Tai San Noah Lim
Directeur/Bestuurslid bij Mirxes Holding Co., Ltd.
Profiel
Tai San Noah Lim is an Independent Non-Executive Director at Mirxes Holding Co., Ltd.
He holds a graduate degree and a doctorate from the University of Pennsylvania, which he received in 2003 and 2005 respectively.
He also holds an undergraduate degree from the National University of Singapore, which he received in 1999.
Actieve functies van Tai San Noah Lim
Bedrijven | Functie | Begin |
---|---|---|
Mirxes Holding Co., Ltd.
Mirxes Holding Co., Ltd. Financial ConglomeratesFinance Mirxes Holding Co., Ltd. operates as an investment holding company. It is engaged in developing and commercializing blood-based miRNA test kit products for the early detection of cancer and other diseases. The firm’s business segments include Infectious Diseases and Early Detection and Precision Multi-Omics. The Infectious Diseases segment engages in development, manufacture, supply of diagnostic kits and provision of infectious disease clinical testing. The Early Detection and Precision Multi-Omics involves in Development, manufacture, supply of diagnostic & life sciences products, and provision of research profiling, clinical testing and clinical services. The company was founded by Too Heng Phon, Zhou Lihan and Zou Ruiyang in 2014 and is headquartered in Singapore. | Directeur/Bestuurslid | 01-01-2021 |
Opleiding van Tai San Noah Lim
National University of Singapore | Undergraduate Degree |
University of Pennsylvania | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Mirxes Holding Co., Ltd.
Mirxes Holding Co., Ltd. Financial ConglomeratesFinance Mirxes Holding Co., Ltd. operates as an investment holding company. It is engaged in developing and commercializing blood-based miRNA test kit products for the early detection of cancer and other diseases. The firm’s business segments include Infectious Diseases and Early Detection and Precision Multi-Omics. The Infectious Diseases segment engages in development, manufacture, supply of diagnostic kits and provision of infectious disease clinical testing. The Early Detection and Precision Multi-Omics involves in Development, manufacture, supply of diagnostic & life sciences products, and provision of research profiling, clinical testing and clinical services. The company was founded by Too Heng Phon, Zhou Lihan and Zou Ruiyang in 2014 and is headquartered in Singapore. | Finance |